A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04937319 In Overweight And Obese Otherwise Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2012
At a glance
- Drugs PF 4937319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2012 New trial record